BG60496B2 - Метод за получаване на структурно хомогенни форми на производни на тиазола - Google Patents

Метод за получаване на структурно хомогенни форми на производни на тиазола Download PDF

Info

Publication number
BG60496B2
BG60496B2 BG098384A BG9838494A BG60496B2 BG 60496 B2 BG60496 B2 BG 60496B2 BG 098384 A BG098384 A BG 098384A BG 9838494 A BG9838494 A BG 9838494A BG 60496 B2 BG60496 B2 BG 60496B2
Authority
BG
Bulgaria
Prior art keywords
famotidine
solution
forms
melting point
compound
Prior art date
Application number
BG098384A
Other languages
Bulgarian (bg)
English (en)
Inventor
Peter Bod
Kalman Harsanyi
Bela Hegedues
Eric Bogsch
Eva Fekecs
Imre Peter
Zsuzsanna Aracs Trischler
Sandor Miszori
Maria Stiller
Original Assignee
Richter Gedeon Vegyeszeti Gyar Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10963778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG60496(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Richter Gedeon Vegyeszeti Gyar Rt. filed Critical Richter Gedeon Vegyeszeti Gyar Rt.
Publication of BG60496B2 publication Critical patent/BG60496B2/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG098384A 1986-08-05 1994-01-18 Метод за получаване на структурно хомогенни форми на производни на тиазола BG60496B2 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU863370A HU196775B (en) 1986-08-05 1986-08-05 Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances

Publications (1)

Publication Number Publication Date
BG60496B2 true BG60496B2 (bg) 1995-05-31

Family

ID=10963778

Family Applications (1)

Application Number Title Priority Date Filing Date
BG098384A BG60496B2 (bg) 1986-08-05 1994-01-18 Метод за получаване на структурно хомогенни форми на производни на тиазола

Country Status (18)

Country Link
US (3) US4894459A (cs)
EP (1) EP0256747B2 (cs)
JP (2) JP2644234B2 (cs)
KR (1) KR940003954B1 (cs)
CN (1) CN1024275C (cs)
AR (1) AR243175A1 (cs)
AT (1) ATE82274T1 (cs)
AU (1) AU604040B2 (cs)
BG (1) BG60496B2 (cs)
CA (1) CA1265809A (cs)
CS (1) CS268188B2 (cs)
DE (2) DE3782576T3 (cs)
DK (1) DK175022B1 (cs)
FI (1) FI89917C (cs)
GR (1) GR871216B (cs)
HU (1) HU196775B (cs)
PH (1) PH24069A (cs)
PT (1) PT85473B (cs)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO882037L (no) * 1987-06-22 1988-12-23 Marga Para La Investigacion Sa Famotidin, polymerte former og fremstilling derav.
ES2162867T3 (es) * 1993-07-09 2002-01-16 Scherer Corp R P Metodo de fabricacion de formas de dosificacion de farmacos liofilizados.
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
CA2426122A1 (en) * 2002-05-02 2003-11-02 M/S Tonira Pharma Limited A process for the preparation of a combination of famotidine polymorphis a and b
TW200409746A (en) * 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
EP2156839A1 (en) 2002-12-11 2010-02-24 Taro Pharmaceutical Industries Ltd. Method of treating movement disorders using barbituric acid derivatives
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
WO2006003651A2 (en) * 2004-07-02 2006-01-12 Taro Pharmaceutical Industries, Ltd A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20070043097A1 (en) * 2005-07-18 2007-02-22 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
CA2657928C (en) 2006-07-18 2014-12-02 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
WO2008027963A2 (en) * 2006-08-31 2008-03-06 Horizon Therapeutics, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
EP2081576A4 (en) * 2006-11-14 2010-06-30 Taro Pharmaceuticals North Ame METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
TW201011043A (en) * 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
TR201618765A2 (tr) 2016-12-16 2018-07-23 Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi Ağrı ve enflamasyonun tedavisi için steroid olmayan anti-enflamatuvar ilaçlar ve H2 reseptörü antagonisti kombinasyonları.
WO2022015784A1 (en) 2020-07-15 2022-01-20 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1543238A (en) * 1976-09-21 1979-03-28 Smith Kline French Lab Polymorph of cimetidine
JPS6056143B2 (ja) * 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
JPS5655383A (en) * 1979-10-12 1981-05-15 Yamanouchi Pharmaceut Co Ltd Amizine derivative and its preparation
HU185457B (en) * 1981-09-25 1985-02-28 Richter Gedeon Vegyeszet Process for preparating cimetidine-z
US4496737A (en) * 1982-09-27 1985-01-29 Merck & Co., Inc. Process for preparing sulfamylamidine antisecretory agents
JPS59227870A (ja) * 1983-06-07 1984-12-21 Yamanouchi Pharmaceut Co Ltd 新規２−グアニジノチアゾリン誘導体ならびにその製造法
HU194845B (en) * 1985-09-11 1988-03-28 Richter Gedeon Vegyeszet Process for production of n-sulphamil-3-/2-guanidintiazolil-4-methil-tio/-propion-amidin
DE3644246A1 (de) * 1986-06-20 1987-12-23 Uriach & Cia Sa J Verfahren zur herstelung von 3-(((2-((aminoiminomethyl)-amino)-4-thiazolyl)-methyl)-thio)-n-(aminosulfonyl)-propanimidamid
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
NO882037L (no) * 1987-06-22 1988-12-23 Marga Para La Investigacion Sa Famotidin, polymerte former og fremstilling derav.

Also Published As

Publication number Publication date
FI873346L (fi) 1988-02-06
DK175022B1 (da) 2004-04-26
AU7654287A (en) 1988-02-11
FI873346A0 (fi) 1987-08-03
EP0256747B2 (en) 2001-11-28
AR243175A1 (es) 1993-07-30
CA1265809A (en) 1990-02-13
CS268188B2 (en) 1990-03-14
JPS6399065A (ja) 1988-04-30
PT85473B (pt) 1990-06-29
US5128477A (en) 1992-07-07
KR880002847A (ko) 1988-05-11
PH24069A (en) 1990-03-05
DK404187D0 (da) 1987-08-03
ATE82274T1 (de) 1992-11-15
JP2644234B2 (ja) 1997-08-25
US5120850A (en) 1992-06-09
JP2708715B2 (ja) 1998-02-04
DK404187A (da) 1988-02-06
US4894459A (en) 1990-01-16
DE3782576T2 (de) 1993-03-25
AU604040B2 (en) 1990-12-06
CN1024275C (zh) 1994-04-20
FI89917C (fi) 1993-12-10
JPH07316141A (ja) 1995-12-05
CS579987A2 (en) 1989-04-14
HU196775B (en) 1989-01-30
DE3782576D1 (de) 1992-12-17
PT85473A (en) 1987-09-01
KR940003954B1 (ko) 1994-05-09
CN87105373A (zh) 1988-06-08
DE3782576T3 (de) 2002-08-08
GR871216B (en) 1987-11-19
EP0256747A1 (en) 1988-02-24
FI89917B (fi) 1993-08-31
HUT45240A (en) 1988-06-28
DE256747T1 (de) 1988-11-24
EP0256747B1 (en) 1992-11-11

Similar Documents

Publication Publication Date Title
BG60496B2 (bg) Метод за получаване на структурно хомогенни форми на производни на тиазола
Pikal et al. Quantitative crystallinity determinations for β-lactam antibiotics by solution calorimetry: Correlations with stability
ES2336287T5 (es) Modificaciones polimórficas de ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxílico y procedimientos para su preparación
US20070128731A1 (en) Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
CN102702008B (zh) 阿戈美拉汀硫酸复合物及其制备方法
US9527803B2 (en) Crystal form VII of agomelatine, preparation method and use thereof and pharmaceutical composition containing same
WO2007080362A1 (en) Pharmaceutically acceptable co-crystalline forms of sildenafil
AT398204B (de) Mono-(2-ammonium-2-hydroxymethyl-1,3-propandiol (2r,cis)-1,2-epoxypropylphosphonat und verfahren zu dessen herstellung sowie pharmazeutische zusammensetzungen
CN108341818A (zh) 巴瑞克替尼及其磷酸盐的新晶型及其制备方法
CN115843298B (zh) 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型
CN106905216A (zh) 一种质子泵抑制剂药物化合物及其制备方法
FI82457B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbar kristallform çaçav 1-benzhydyl-4 -allylpiperazindihydroklorid.
CN114349770B (zh) 一种凝血FXa抑制剂的制备方法
CN117003701B (zh) 氟胞嘧啶-异乳清酸盐及其制备方法和应用
KR20070034011A (ko) 토실산 서플라타스트 결정의 균일성의 평가방법 및 균일한결정 및 그의 제조방법
CN119019403A (zh) 优克那非晶型及其制备方法
TW202430513A (zh) 吡啶多取代化合物的鹽型、晶型及其製備方法
CN105055425A (zh) 一种治疗脑缺血的药物盐酸法舒地尔组合物颗粒剂
BIRÉ A new cocrystallization method: Non-Photochemical Laser-Induced Nucleation (NPLIN) of a cocrystal of caffeine–gallic acid in water
CN105193711A (zh) 一种治疗脑血管疾病的药物盐酸法舒地尔组合物水针剂